| Postmenopausal hormone therapy and breast cancer: what is the problem? | |
| | |
MedLine Citation:
|
PMID: 15883112 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Observational studies provide evidence that breast cancer risk is increased with long-term oral use of postmenopausal estrogen replacement therapy (ET). Various large cohort studies have shown that the addition of a progestogen in combined hormone replacement therapy (EPT) increases this risk further. Prospective, randomized controlled trials have confirmed this for the continuous combined regimen. So, why not tell our patients, "Stop using ET and EPT, it is dangerous to your health!"? The answer is: there are too many problems to allow such an oversimplified, definite statement. What is the problem? There is more than one! The problems are as follows: In conclusion, we have a problem as we cannot formulate any general advice that holds for the majority of European postmenopausal women due to lack of consistency, lack of biological plausibility, and lack of relevance of randomized clinical trial data to our daily practical work. So, we have a problem and not a firm basis for undisputable statements. |
| | |
Authors:
|
Peter Kenemans |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Maturitas Volume: 51 ISSN: 0378-5122 ISO Abbreviation: Maturitas Publication Date: 2005 May |
Date Detail:
|
Created Date: 2005-05-10 Completed Date: 2005-12-22 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7807333 Medline TA: Maturitas Country: Ireland |
Other Details:
|
Languages: eng Pagination: 75-82 Citation Subset: IM |
Affiliation:
|
Department of Obstetrics and Gynaecology, VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands. kenemans@vumc.nl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Breast Neoplasms
/
chemically induced* Estrogen Replacement Therapy / adverse effects* Evidence-Based Medicine Female Humans Postmenopause Progestins / administration & dosage*, adverse effects Randomized Controlled Trials as Topic Risk Factors |
| Chemical | |
Reg. No./Substance:
|
0/Progestins |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Controversies about HRT--lessons from monkey models.
Next Document: Breast cancer risk in the WHI study: the problem of obesity.